P-selectin inhibitor, compositions thereof and methods of use thereof

Case ID:
C16415

Unmet Need

COVID-19 is characterized by vascular inflammation and thrombosis, including elevations in P-selectin, a mediator of inflammation released by endothelial cells.  Patients with serious infection are more likely to have COVID-19 associated coagulopathy than patients with mild infection, and those who die from COVID-19 are more likely to have met the coagulopathy criteria. Thus, hospitalized COVID-19 patients in U.S. are given anticoagulants, mainly heparins, for prophylaxis or treatment. However, no specific antithrombotic treatment has shown to be promising in decreasing in-hospital mortality so far. Hence, novel strategies to treat coagulopathy in COVID-19 patients are urgently needed.

 

 

Technology Overview

The invention describes a method to use an inhibitor of P-selectin to treat COVID-19 patients with coagulopathy. The inventor proposed that COVID-19 causes endothelial injury, leading to microvascular inflammation and microvascular thrombosis in COVID-19 patients. As P-selectin mediates the initial rolling of leukocytes onto the inflamed endothelium and activates monocytes to synthesize tissue factor, an essential cofactor in the initiation of the extrinsic pathway of blood coagulation, the inventor proposed that a P-selectin inhibitor will decrease vascular inflammation and vascular thrombosis in COVID-19 patients and improve their treatment outcomes. Several recent publications on COVID-19 associated coagulopathy have supported P-selectin as a potential therapeutic target.

 

Stage of Development

The inventor has completed a clinical trial with Novartis (NCT04435184) to test crizanlizumab’s safety and efficacy in improving outcomes of COVID-19 patients.

We tested the effect of P-selectin inhibition on biomarkers of thrombosis and inflammation in patients with COVID-19. Hospitalized patients with moderate COVID-19 were randomly assigned to receive either placebo or crizanlizumab, a P-selectin inhibitor, in a double-blind fashion. Crizanlizumab reduced P-selectin levels by 89%. Crizanlizumab increased D-dimer levels by 77% and decreased prothrombin fragment. There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19. (Crizanlizumab for Treating COVID-19 Vasculopathy


 

Publication

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial - ScienceDirect


Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
P-SELECTIN INHIBITOR, COMPOSITIONS THEREOF AND METHODS OF USE THEREOF ORD: Ordinary Utility United States 17/842,580   6/16/2022     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum